Phase 3 Results for Ixekizumab Promising in Patients with Non-Radiographic Axial Spondyloarthritis

The frequency of adverse events and serious adverse events, including those that led to therapy discontinuation, was low and similar across all study groups. No new safety signals were identified.

This study showed that adding ixekizumab to conventional background medications was superior to conventional background medication alone for improving the signs, symptoms and inflammation on MRI in patients with non-radiographic axSpA.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

1. Deodhar A, van der Heijde D, Gensler L, et al. Ixekizumab in non-radiographic axial spondyloarthritis: Primary results from a phase 3 trial [abstract #2729]. Arthritis Rheumatol. 2019 Oct; 71(suppl 10).